All In Biotech

NDA 209296 · Heron Theraps INC

Cinvanti

Aprepitant · Intravenous · Substance P/Neurokinin-1 Receptor Antagonist

Last checked: Nov 20, 2026Latest source record: Mar 5, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Nov 9, 2017

Approved uses

3

Original approval plus efficacy supplements

Registered trials

215

62 Phase 3, 9 recruiting

FAERS reports

7,525

7,148 serious, 1,480 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 1, 2026.

CINVANTI, in combination with other antiemetic agents, is indicated in adults for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin as a single-dose regimen. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) as a single-dose regimen. nausea and vomiting associated with initial and repeat courses of MEC as a 3-day regimen. CINVANTI is a substance P/neurokinin-1 (NK 1 ) receptor antagonist, indicated in adults, in combination with other antiemetic agents, for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin as a single-dose regimen. ( 1 ) delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) as a single-dose regimen. ( 1 ) nausea and vomiting associated with initial and repeat courses of MEC as a 3-day regimen. ( 1 ) Limitations of Use : CINVANTI has not been studied for treatment of established nausea and vomiting. ( 1 ) Limitations of Use CINVANTI has not been studied for the treatment of established nausea and vomiting.

Mechanism: Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK 1 ) receptors. Aprepitant has little or no affinity for serotonin (5-HT 3 ), dopamine, and corticosteroid receptors. Aprepitant has been shown in animal models to inhibit emesis induced by cytotoxic chemotherapeutic agents, such as cisplatin, via central actions. Animal and human Positron Emission Tomography (PET) studies with aprepitant have shown that it crosses the blood brain barrier and occupies brain NK 1 receptors. Animal and human studies show that aprepitant augments the antiemetic activity of...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • CINVANTI · APREPITANT 130MG/18ML (7.2MG/ML) · EMULSION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Aprepitant" as an intervention, any sponsor and status, largest first.

All 215 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue1,297
  • nausea1,128
  • pyrexia924
  • off label use889
  • alopecia825
  • dyspnoea824
  • diarrhoea784
  • rash768
  • vomiting714
  • hypersensitivity705
  • infusion related reaction695
  • pain693

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20047
200515
200628
200724
200829
200948
201066
2011105
2012141
2013169
2014160
2015228
2016393
2017164
2018362
2019447
2020508
2021677
2022642
2023763
20241,036
2025905
2026608

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cinvanti (Aprepitant)

2024 spending

$289K

Beneficiaries

149

497 claims

Per beneficiary

$1,939

$23.15 per unit

View as table
YearSpending
2020$54,704
2021$271,608
2022$150,018
2023$141,770
2024$288,945

Part B: Cinvanti (Aprepitant) · HCPCS J0185

2024 spending

$42.3M

Beneficiaries

40,602

181,746 claims

Per beneficiary

$1,041

2024 ASP limit $1.72 per unit

View as table
YearSpending
2020$39,325,804
2021$27,803,163
2022$35,607,662
2023$40,374,151
2024$42,285,416

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 324 on PubMed

Sponsor: Heron Theraps INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.